Compare · AMGN vs VCEL
AMGN vs VCEL
Side-by-side comparison of Amgen Inc. (AMGN) and Vericel Corporation (VCEL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AMGN and VCEL operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- AMGN is the larger of the two at $239.09B, about 108.0x VCEL ($2.21B).
- Over the past year, AMGN is up 52.8% and VCEL is up 18.3% - AMGN leads by 34.5 points.
- AMGN has been more active in the news (18 items in the past 4 weeks vs 2 for VCEL).
- AMGN has more recent analyst coverage (25 ratings vs 11 for VCEL).
- Company
- Amgen Inc.
- Vericel Corporation
- Price
- $442.23-0.36%
- $43.19+1.94%
- Market cap
- $239.09B
- $2.21B
- 1M return
- +17.61%
- -4.66%
- 1Y return
- +52.83%
- +18.34%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1983
- News (4w)
- 18
- 2
- Recent ratings
- 25
- 11
Amgen Inc.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and a strategic research and development collaboration with Neumora Therapeutics, Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Vericel Corporation
Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product includes, NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
Latest AMGN
- SVP, Business Development Khosla Rachna exercised 1,252 shares at a strike of $162.60 and sold $1,346,499 worth of shares (3,252 units at $414.05), decreasing direct ownership by 24% to 6,404 units (SEC Form 4) to satisfy tax liability
- VP, Finance & CAO Busch Matthew C. was granted 730 shares, increasing direct ownership by 17% to 5,080 units (SEC Form 4)
- Director Ishrak Omar was granted 85 shares, increasing direct ownership by 1% to 7,486 units (SEC Form 4)
- Director Holley Charles M was granted 103 shares, increasing direct ownership by 0.80% to 12,990 units (SEC Form 4)
- Director Drake Michael V was granted 64 shares, increasing direct ownership by 1% to 5,876 units (SEC Form 4)
- SVP, Human Resources Miller Derek exercised 3,890 shares at a strike of $169.56 and sold $1,565,898 worth of shares (3,890 units at $402.54) (SEC Form 4) (tax liability)
- SVP & CCO Grygiel Nancy A. exercised 2,970 shares at a strike of $177.41 and sold $1,194,415 worth of shares (2,970 units at $402.16) (SEC Form 4) (for withholding tax)
- Truist reiterated coverage on Amgen with a new price target
- Oppenheimer reiterated coverage on Amgen with a new price target
- Morgan Stanley reiterated coverage on Amgen with a new price target
Latest VCEL
- Cosmetic Surgery's Next Debate: Rebuild Tissue, Not Fill It
- Chief Operating Officer Halpin Michael exercised 10,000 shares at a strike of $16.66 and sold $468,400 worth of shares (10,000 units at $46.84) as part of a pre-agreed trading plan (SEC Form 4)
- Principal Accounting Officer Siegal Jonathan exercised 4,500 shares at a strike of $31.51 and sold $220,050 worth of shares (4,500 units at $48.90) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 10-Q filed by Vericel Corporation
- Vericel Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Vericel Reports Second Quarter 2026 Financial Results, Raises Full-Year Financial Guidance and Announces Share Repurchase Program
- Vericel to Report Second Quarter 2026 Financial Results on July 30, 2026
- Principal Accounting Officer Siegal Jonathan exercised 2,500 shares at a strike of $29.82 and sold $122,667 worth of shares (2,732 units at $44.90) as part of a pre-agreed trading plan, decreasing direct ownership by 21% to 886 units (SEC Form 4)
- Chief Financial Officer Mara Joseph Anthony Jr sold $223,750 worth of shares (5,000 units at $44.75) as part of a pre-agreed trading plan, decreasing direct ownership by 24% to 16,009 units (SEC Form 4)
- Chief Medical Officer Hopper Jonathan Mark sold $450,000 worth of shares (10,000 units at $45.00) as part of a pre-agreed trading plan and exercised 10,000 shares at a strike of $29.82 (SEC Form 4)